Our study demonstrates that ASO-mediated suppression of Snca prevented and reversed the progression of aSyn-mediated pathology in rodent transmission models of PD, demonstrating the potential of SNCA ASOs as a therapy for PD patients. This evidence concerns the gene SNCA and Parkinson disease.